Synbiotic (Lactiplantibacillus pentosus GSSK2 and isomalto-oligosaccharides) supplementation modulates pathophysiology and gut dysbiosis in experimental metabolic syndrome.

Metabolic syndrome a lifestyle disease, where diet and gut microbiota play a prodigious role in its initiation and progression. Prophylactic bio-interventions employing probiotics and prebiotics offer an alternate nutritional approach towards attenuating its progression. The present study aimed to evaluate the protective efficacy of a novel synbiotic (Lactiplantibacillus pentosus GSSK2 + isomalto-oligosaccharides) in comparison to orlistat in an experimental model of metabolic syndrome. It was observed that supplementation of synbiotic for 12 weeks to Sprague Dawley rats fed with high fat diet (HFD), ameliorated the morphometric parameters i.e. weight gain, abdominal circumference, Lee's index, BMI and visceral fat deposition along with significantly increased fecal Bacteroidetes to Firmicutes ratio, elevated population of Lactobacillus spp., Akkermansia spp., Faecalibacterium spp., Roseburia spp. and decreased Enterobacteriaceae compared with HFD animals. Additionally, synbiotic administration to HFD animals exhibited improved glucose clearance, lipid biomarkers, alleviated oxidative stress, prevented leaky gut phenotype, reduced serum lipopolysaccharides and modulated the inflammatory, lipid and glucose metabolism genes along with restored histomorphology of adipose tissue, colon and liver compared with HFD animals. Taken together, the study highlights the protective potential of synbiotic in comparison with its individual components in ameliorating HFD-induced metabolic complications.

Administration of indigenous probiotics modulate high-fat diet-induced metabolic syndrome in Sprague Dawley rats.

Modulation of the gut microbiota by probiotics, is emerging as a promising approach for the management of metabolic diseases but due to their species and strain specific response, isolation of new probiotic strains is gaining importance. The present study was designed to assess the effect of isolated and well characterised indigenous probiotics, Lactobacillus pentosus GSSK2, Lactobacillus fermentum PUM and Lactobacillus plantarum GS26A in high fat diet (HFD) induced metabolic syndrome. It was observed that though supplementation of all three probiotics for 12 weeks to Sprague Dawley rats fed with HFD, ameliorated the anthropometric parameters, but L. pentosus GSSK2 showed maximum reduction in weight gain while maximum decrease in abdominal circumference, Lee's index, BMI and visceral fat deposition was observed in L. plantarum GS26A compared with HFD animals. Further, administration of L. plantarum GS26A to HFD animals led to significant increase in lactic acid bacteria count and lipid excretion in feces followed by L. pentosus GSSK2 and L. fermentum PUM compared with counter controls. Additionally, both L. pentosus GSSK2 and L. plantarum GS26A exhibited improved glucose tolerance, liver biomarkers, alleviated oxidative stress and restored the histoarchitechture of adipose tissue, colon and liver compared with HFD animals. The study highlights the prophylactic potential of isolated probiotics in experimental metabolic syndrome model and revealed that amongst all three probiotics, L. pentosus GSSK2 and L. plantarum GS26A were equally effective and more promising than L. fermentum PUM in improving metabolic dysfunctions and may be employed as functional foods but needs to be correlated clinically.

Isolation, characterization and anti-inflammatory mechanism of probiotics in lipopolysaccharide-stimulated RAW 264.7 macrophages.

Probiotics are known to modulate gut microbiota, intestinal barrier function and host immune response, but due to the species and strain specific response their mechanisms are not clearly understood. Thus, the present study was designed to isolate, assess the anti-inflammatory potential and underlying modulatory mechanisms of indigenous probiotics in murine macrophage cell line, RAW 264.7. Forty lactic acid bacteria (LAB) were isolated from different sources and monitored for their anti-inflammatory potential against lipopolysaccharide (LPS) induced inflammatory stress employing RAW 264.7 cells. Among these isolates, only four LAB isolates exhibited more than 90% nitric oxide inhibition and possessed the probiotic attributes. Further, these selected LAB isolates reduced the level of pro-inflammatory cytokines, TNF-α, IL-1ß and IL-6, inhibited the phosphorylation of Mitogen Activated Protein Kinases (MAPKs) i.e. p38 MAPK, ERK1/2 and SAPK/JNK and expression of cyclooxygenase-2 (COX-2) in LPS stimulated RAW 264.7 cells. The in vitro analysis suggested that the selected probiotic isolates attenuated the LPS-induced inflammation by downregulating MAPK pathway vis-a-vis inhibiting COX-2 and can be employed as anti-inflammatory agents in various inflammatory diseases.